Full-Time

Staff Scientist

R&D, Women's Health

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions provider

Compensation Overview

$148k - $185.1k/yr

Senior, Expert

Company Historically Provides H1B Sponsorship

San Carlos, CA, USA

Category
Lab & Research
Life Sciences
Medical Research
Required Skills
Data Analysis
Requirements
  • Ph.D. in molecular biology or closely related field
  • Minimum of 8 years of industry experience or 2 years of post-doctoral research + 6 years of industry experience
Responsibilities
  • Contributes substantially and intellectually to research and development
  • Independently leads projects to create and develop novel nucleic acid based diagnostic tests; including planning, feasibility testing, protocol development, and optimization
  • Responsible for executing projects as per associated timelines and deliverables
  • Thoroughly comprehends the objectives and vision of the work
  • Develops plans, generates and advances new ideas
  • Performs basic data analysis, including statistics
  • Independently designs and executes moderate to high complexity experiments
  • Coordinates the execution and analysis of effective experiments with statistics and bioinformatics teams
  • Documents research progress under a Quality Management System
  • May manage Research Associates
  • May work with partners and outside collaborators
  • Communicates progress directly with colleagues and senior management
Desired Qualifications
  • Experience developing tests in NIPT and/or liquid biopsy highly desirable
  • Multiomics, epigenetic/methylation, target enrichment, cfDNA/RNA experience is a plus
  • Bioinformatic capabilities, programming (e.g. PERL, python) and databases experience (SQL) are a plus

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering personalized genetic counseling services alongside their testing, allowing patients to receive tailored guidance. The company's goal is to improve patient care through precise genetic insights.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for non-invasive cancer monitoring boosts Natera's Signatera test adoption.
  • Telehealth expansion supports Natera's remote genetic counseling services.
  • Rising organ transplant procedures increase demand for Natera's Prospera test.

What critics are saying

  • Increased competition from companies like Lantheus may impact Natera's market share.
  • Natera's CFO selling stock could indicate potential internal concerns.
  • Reliance on insurance reimbursements poses a risk if healthcare policies change.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for prenatal, oncology, and transplant health.
  • The company offers the unique Signatera test for personalized cancer monitoring.
  • Natera's Prospera Heart test uses a novel Donor Quantity Score for transplant rejection detection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

5%
Simply Wall St
Mar 13th, 2025
Natera (NasdaqGS:NTRA) Welcomes Former National Cancer Institute Director Back to Board

Last week, Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli.

Investing.com
Mar 10th, 2025
Natera launches HEROES trial for breast cancer treatment

Natera launches HEROES trial for breast cancer treatment.

Financial Modeling Prep
Feb 28th, 2025
Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates Strong Capital Efficiency

Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.

BioSpace
Feb 19th, 2025
Natera To Report Its Fourth Quarter And Full Year Results On February 27, 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m

MarketBeat
Nov 24th, 2024
Alpha DNA Investment Management LLC Invests $505,000 in Natera, Inc. (NASDAQ:NTRA)

Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).